SEARCH

SEARCH BY CITATION

  • 1
    Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 2003; 92: 25761
  • 2
    Kirby RS. Doxazosin in benign prostatic hyperplasia. effects on blood pressure and urinary flow in normotensive and hypertensive men. Urology 1995; 46: 1826
  • 3
    Kirby RS. Terazosin in benign prostatic hyperplasia. effects on blood pressure in normotensive and hypertensive men. Br J Urol 1998; 82: 3739
  • 4
    The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. NIH Publication 03–5233: NIH, May 2003
  • 5
    Di Priolo L, Priore P, Gocco C et al. Dose-titration study of alfuzosin, a new alpha1-adrenoceptor blocker, in essential hypertension. Eur J Clin Pharmacol 1988; 35: 2530
  • 6
    Sega R, Marazzi ME, Bombelli M et al. Comparison of the new alpha1-blocker, alfuzosin with propranolol as first-line therapy in hypertension. Pharmacol Res 1991; 24: 4152